SEC Filing Form 4: Insider Transaction for Apogee Therapeutics, Inc.

Michael Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc. (APGE), reported a transaction on April 16, 2026. Henderson acquired 3,000 shares of Common Stock at a price of $22.86 per share, increasing his direct ownership to 1,135,987 shares. Additionally, Henderson was granted a stock option to purchase 3,000 shares of Common Stock at a price of $22.86 per share. This option is part of a larger grant that vests over four years, subject to continued service. Following this, his indirect ownership of stock options stands at 387,012 shares. The filing was signed on April 20, 2026, by Matthew Batters as attorney-in-fact for Michael Henderson.